Published in J Clin Invest on June 01, 1968
Plasminogen activator activity in cultures from human tissues. An immunological and histochemical study. J Clin Invest (1969) 1.33
Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol (1984) 1.13
Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase. J Clin Invest (1982) 1.04
Protease effects on specific growth properties of normal and transformed baby hamster kidney cells. Proc Natl Acad Sci U S A (1977) 0.80
Purification of plasminogen activators from human seminal plasma. Biochem J (1978) 0.75
HOMOTRANSPLANTATION OF THE LIVER IN HUMANS. Surg Gynecol Obstet (1963) 10.22
The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys (1952) 9.50
The mechanism of clot dissolution by plasmin. J Clin Invest (1959) 7.16
xi-Aminocaproic acid: an inhibitor of plasminogen activation. J Biol Chem (1959) 6.05
Studies on enhanced fibrinolytic activity in man. J Clin Invest (1959) 3.93
A new method of large-scale preparation of hypertensin, with a note on its assay. Biochem J (1955) 3.03
ABNORMAL PLASMINOGEN-PLASMIN SYSTEM ACTIVITY (FIBRINOLYSIS) IN PATIENTS WITH HEPATIC CIRRHOSIS: ITS CAUSE AND CONSEQUENCES. J Clin Invest (1964) 2.52
The activation of human plasminogen by streptokinase. J Biol Chem (1955) 2.05
Tissue activators of plasminogen. Fed Proc (1990) 1.62
The fibrinolytic activity of urine. Br J Exp Pathol (1951) 1.52
The quantitative determination of renin in the plasma of patients with arterial hypertension. Circulation (1963) 1.48
An activator of plasminogen in normal urine. Proc Soc Exp Biol Med (1952) 1.46
Comparative activity of thrombin on substituted arginine and lysine esters. Am J Physiol (1965) 1.28
The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry (1966) 1.24
The biochemistry and physiology of urokinase. Am J Cardiol (1960) 1.18
Origin of fibrinolytic activity in cultures of the human kidney. J Lab Clin Med (1967) 1.17
Tissue fibrinolytic activity studied by a histochemical method. Fed Proc (1990) 1.15
CRYSTALLINE HUMAN UROKINASE: SOME PROPERTIES. Science (1965) 1.03
The kidneys and the liver as the organs regulating the fibrinolytic system of the circulating blood. Thromb Diath Haemorrh (1966) 1.00
PARTIAL PURIFICATION AND PROPERTIES OF THE PLASMINOGEN ACTIVATOR FROM PIG HEART. Biochemistry (1964) 0.95
The mechanism of inhibition of papain by its specific antibodies. Biochemistry (1967) 0.93
Fibrinolytic activity of urine. Scand J Clin Lab Invest (1952) 0.92
On the controlling function of the kidneys in fibrinolysis. Experientia (1962) 0.92
ASSAY OF UROKINASE PREPARATIONS WITH THE SYNTHETIC SUBSTRATE ACETYL-L-LYSINE METHYL ESTER. J Lab Clin Med (1964) 0.91
Inhibition of dog fibrinolytic system in experimental tubular necrosis of kidney. Experientia (1964) 0.90
Urokinase levels in urine after nicotinic acid injection. Thromb Diath Haemorrh (1966) 0.89
Improved procedure for the isolation of human plasminogen. J Biol Chem (1961) 0.88
FIBRINOLYSIS AND FIBRINOGEN BREAKDOWN PRODUCTS (ANTITHROMBIN VI) IN RENAL VENOUS BLOOD (RVB) IN DOG. Thromb Diath Haemorrh (1964) 0.84
Urokinase excretion in man: a method of determination and consideration of its significance. Thromb Diath Haemorrh (1960) 0.82
Mechanism of action and some properties of a tissue activator of plasminogen. Thromb Diath Haemorrh (1965) 0.81
INVESTIGATIONS ON THE INHIBITORS OF THE FIBRINOLYTIC SYSTEM. Thromb Diath Haemorrh (1964) 0.78
Studies on urokinase. Some physiological considerations concerning normal urokinase excretion. Clin Chim Acta (1966) 0.78
A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature (2001) 42.18
THE EFFECT IN PATIENTS OF STREPTOCOCCAL FIBRINOLYSIN (STREPTOKINASE) AND STREPTOCOCCAL DESOXYRIBONUCLEASE ON FIBRINOUS, PURULENT, AND SANGUINOUS PLEURAL EXUDATIONS. J Clin Invest (1949) 8.50
Thrombolytic therapy: current status (1). N Engl J Med (1988) 5.44
THE VITAMIN C REQUIREMENT OF MAN. ESTIMATED AFTER PROLONGED STUDIES OF THE PLASMA CONCENTRATION AND DAILY EXCRETION OF VITAMIN C IN 3 ADULTS ON CONTROLLED DIETS. J Clin Invest (1939) 2.43
Biologic effects of transdermal estradiol. N Engl J Med (1986) 2.24
Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ (1995) 2.10
Tamm-Horsfall urinary glycoprotein. The chemical composition. Biochem J (1970) 1.77
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest (1969) 1.52
Coronary thrombosis in myocardial infarction. Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Am J Cardiol (1974) 1.51
Thrombolytic therapy: current status (2). N Engl J Med (1988) 1.49
The kallikreinogen-kallikrein enzyme system of human plasma. Assay of components and observations in disease states. Ann Intern Med (1969) 1.45
Detection of serum fibrinogen and fibrin degradation products. Comparison of six technics using purified products and application in clinical studies. Am J Med (1971) 1.41
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. J Clin Invest (1969) 1.34
The preparation and properties of human fibrinogen of relatively high solubility. Biochemistry (1966) 1.31
Current status of antithrombotic therapy in cardiovascular disease. Prog Cardiovasc Dis (1977) 1.31
THE MECHANISM OF THE EXCRETION OF VITAMIN C BY THE HUMAN KIDNEY AT LOW AND NORMAL PLASMA LEVELS OF ASCORBIC ACID. J Clin Invest (1940) 1.30
Comparative activity of thrombin on substituted arginine and lysine esters. Am J Physiol (1965) 1.28
Fibrinolysis. Annu Rev Med (1968) 1.20
Tamm-Horsfall urinary glycoprotein. The subunit structure. Biochem J (1970) 1.20
A pilot study of urokinase therapy in cerebral infarction. Stroke (1976) 1.19
Human fibrinogen of relatively high solubility. Comparative biophysical, biochemical, and biological studies with fibrinogen of lower solubility. Biochemistry (1967) 1.17
The chemical composition and electron microscopic appearance of a protein derived from urinary casts. Biochim Biophys Acta (1970) 1.16
Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol (1997) 1.10
Thrombolytic therapy: reocclusion rates with adjunctive aspirin and its relation to heparin therapy. J Am Coll Cardiol (1992) 1.07
Chronic intravascular coagulation syndrome. N Engl J Med (1968) 1.06
Blood hypercoagulability and thrombosis. Trans Assoc Am Physicians (1970) 1.05
Coronary thrombolysis by intravenous streptokinase in acute myocardial infarction: acute and follow-up studies. Am J Cardiol (1984) 1.03
Nightmares and trauma: a comparison of nightmares after combat with lifelong nightmares in veterans. Am J Psychiatry (1984) 0.99
Editorial: Lwo=dose heparin prophylaxis for postoperative venous thromboembolism. N Engl J Med (1975) 0.98
Coronary thrombolysis for evolving myocardial infarction. Drugs (1984) 0.96
The influence of pregnancy upon blood coagulation and plasma fibrinolytic enzyme function. Am J Obstet Gynecol (1979) 0.93
How does cystitis affect a comparative risk profile of tiaprofenic acid with other non-steroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data. ADR Signals Analysis Project (ASAP) Team. Pharmacol Toxicol (1997) 0.92
Tissue plasminogen activator (t-PA). Will it fulfill its promise? N Engl J Med (1985) 0.92
Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thromb Haemost (1980) 0.92
High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation. Am J Cardiol (1986) 0.88
Sulfinpyrazone: a review of its pharmacological properties and therapeutic use. Drugs (1980) 0.88
The urokinase-pulmonary embolism trial. Circulation (1969) 0.88
High-dose, brief intravenous streptokinase early in acute myocardial infarction. Am Heart J (1982) 0.87
Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction. Am J Med (1987) 0.87
Immunoelectrophoretic characterization of plasma fibrinogen derivatives in patients with pathological plasma proteolysis. J Lab Clin Med (1967) 0.87
[Activity of plasmin and streptokinase-activator on substituted arginine and lysine esters]. Thromb Diath Haemorrh (1966) 0.87
Controlled trial of low-dose heparin and sulfinpyrazone to prevent venous thromboembolism after operation on the hip. J Bone Joint Surg Am (1978) 0.86
Clinical aspects of antiplatelet therapy. Semin Hematol (1985) 0.86
Isolation and characterization of the clottable low molecular weight fibrinogen derived by limited plasmin hydrolysis of human fraction I-4. Biochemistry (1969) 0.86
Clinical trials with antithrombotic and thrombolytic agents. Principles and pitfalls. Thromb Diath Haemorrh (1973) 0.86
Observations on the spontaneous arginine and lysine esterase activity of human plasma, and their relation to Hageman factor. Thromb Diath Haemorrh Suppl (1966) 0.86
Clinical management of the thrombosed vessel: an overview. Angiology (1982) 0.85
Recombinant tissue plasminogen activator (rt-PA): is it the thrombolytic agent of choice for an evolving acute myocardial infarction? Am J Cardiol (1987) 0.84
NCBI genetic resources supporting immunogenetic research. Rev Immunogenet (2000) 0.84
The purification of fibrinogen degradation products by pevikon block electrophoresis. Thromb Diath Haemorrh (1969) 0.84
Fibrinogenolytic dysfibrinogenemias. Fed Proc (1965) 0.83
Pathological fibrinolysis. Fed Proc (1990) 0.83
In vivo transformation between fibrinogens of varying ethanol solubilities: a pathway of fibrinogen catabolism. J Lab Clin Med (1969) 0.83
The urokinase-streptokinase pulmonary embolism trial (phase II) results. Circulation (1974) 0.83
Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke. Stroke (1976) 0.82
Blood coagulation and plasma fibrinolytic enzyme system pathophysiology in stroke. Stroke (1976) 0.82
Fibrinogen catabolism in burned patients. J Trauma (1980) 0.82
Thrombosis prevention. N Engl J Med (1971) 0.82
Reduction in plasma factor 13 (fibrin stabilizing factor) concentration during pregnancy. J Lab Clin Med (1969) 0.82
Course and resolution of the coagulopathy in nephrotic children. Kidney Int (1987) 0.81
Fibrinogen catabolism in the surgically treated patient and in those with postoperative venous thrombosis. Correlation of plasma fibrinogen chromatographic findings with 125I-labeled fibrinogen scan findings. J Lab Clin Med (1977) 0.81
Severe glomerulonephritis complicated by coagulopathy: treatment with anticoaguland and immunosuppresive drugs. J Pediatr (1977) 0.81
Reduction of coagulation factor XIII concentration in patients with myocardial infarction, cerebral infarction, and other thromboembolic disorders. Thromb Haemost (1977) 0.81
Drug safety tests and subsequent clinical experience. J R Soc Med (1978) 0.81
Fibrinolysis and afibrinogenemia. Anesthesiology (1966) 0.81
Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol (1986) 0.80
Intra-arterial thrombolytic therapy in peripheral vascular disease. Surg Gynecol Obstet (1987) 0.80
Pharmacology and pharmacokinetics of platelet-active drugs under current clinical investigation. Adv Prostaglandin Thromboxane Leukot Res (1982) 0.80
Reaction of plasmic degradation products of fibrinogen in the radioimmunoassay of human fibrinopeptide A. Blood (1975) 0.79
The phase II urokinase-streptokinase pulmonary embolism trial: a national cooperative study. Thromb Diath Haemorrh (1975) 0.79
Frustrations with clinical trials. Eur J Clin Pharmacol (1980) 0.79
Personal reflections on the development of thrombolytic therapy and its application to acute coronary thrombosis. Am Heart J (1981) 0.79
Streptokinase therapy for thromboembolic occlusive vascular disease. Ann Intern Med (1971) 0.79
Fibrinolytic mechanisms in tissue injury. Gastroenterology (1966) 0.79
The hematologic consequences of thrombolytic therapy. Prog Hematol (1986) 0.79
The problem of thromboembolic disease. Semin Nucl Med (1977) 0.78
Blood coagulation system pathophysiology in acute myocardial infarction: the influence of anticoagulant treatment on laboratory findings. J Lab Clin Med (1979) 0.78
Formation of soluble fibrin oligomers in purified systems and in plasma. Biochem J (1983) 0.78
The proteolysis of fibrinogen by plasmin: the identification of thrombin-clottable fibrinogen derivatives which polymerize abnormally. J Lab Clin Med (1966) 0.78
The status of information about the use of blood, blood substitutes, and adjuvant solutions for extracorporeal circulation. Transfusion (1967) 0.78
The anturane reinfarction trial. Circulation (1980) 0.77
Plasma fibrinogen and hemostatic functions (pathological and genetic disorders). Prog Hematol (1966) 0.77
The current and future use of thrombolytic therapy. Annu Rev Pharmacol Toxicol (1985) 0.77
Catabolism and excretion of fibrinopeptide-A. Blood (1982) 0.77
An investigation into the suitability of a commercial real-time PCR assay to screen for Taylorella equigenitalis in routine prebreeding equine genital swabs. Equine Vet J (2009) 0.77
A fibrinolytic defect in the respiratory distress syndrome. N Engl J Med (1990) 0.75
Postmarketing surveillance studies. BMJ (1992) 0.75
Acute liver injury associated with amoxicillin-clavulanic acid. Arch Intern Med (1997) 0.75
Prescriber profile and postmarketing surveillance. Lancet (1993) 0.75
Treatment of myocardial infarction. Br Med J (1971) 0.75
Antidepressants and suicide. Antidepressants prescribed for conditions other than depression. BMJ (1995) 0.75
Thrombolytic therapy in surgical patients. Curr Surg (1981) 0.75
Diabetes mellitus: a frequent factor in liability claims. N J Med (1994) 0.75
Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes. Adv Prostaglandin Thromboxane Leukot Res (1982) 0.75